http://www.foxnews.com/health/2010/12/07/study-daily-aspirin-cuts-cancer-risks/#ixzz17RlnbXiH
Published December 07, 2010 | Reuters
Taking low doses of aspirin can reduce the risk of many kinds of cancer, scientists said on Tuesday, and the evidence is strong enough to suggest people over 40 should take it daily as protection.
The findings will fuel an already intense debate about the merits of taking aspirin, which increases the risk of bleeding in the stomach to around one patient in every thousand per year.
In a study of eight trials involving 25,570 patients, researchers found that cancer deaths among those who took aspirin in doses as low as 75 milligrams a day were 21 percent lower during the studies and 34 percent lower after five years.
Aspirin protected people against gastrointestinal cancers the most, the study found, with rates of death from these cancers around 54 percent lower after five years among those who took aspirin compared to those who did not.
Peter Rothwell of Britain's Oxford University said that while taking aspirin carries a small risk of stomach bleeding, that risk was beginning to be "drowned out" by its benefits in reducing the risk of cancer and the risk of heart attacks.
"Previous guidelines have rightly cautioned that in healthy middle-aged people the small risk of bleeding on aspirin partly offsets the benefit from prevention of strokes and heart attacks, but the reductions in deaths due to several common cancers will now alter this balance for many people," he said.
His suggestion was that healthy people could start taking a small 75 mg dose of aspirin every day from the age of about 40 or 45 and continue doing so until they reached around 70 to 75, when the risk of the aspirin causing stomach bleeding rises.
"REMARKABLE DRUG"
Aspirin, originally developed by Bayer, is a cheap over-the-counter drug used for pain and to reduce fever.
Previous studies have found taking aspirin can cut the risk of developing colon or bowel cancer and suggested it does so by blocking the enzyme cyclooxygenase2 which promotes inflammation and cell division and is found in high levels in tumors.
Alastair Watson, professor of translational medicine at the University of East Anglia, said the study was an important step in scientists' understanding of how to prevent cancer.
"It is further proof that aspirin is, by a long way, the most amazing drug in the world," he said.
In Rothwell's study, published in The Lancet, researchers found the 20-year risk of death was reduced by about 10 percent for prostate cancer, 30 percent for lung cancer, 40 percent for colorectal or bowel cancer and 60 percent for esophageal cancer in those taking aspirin.
Reductions in pancreas, stomach and brain cancers were difficult to quantify because of smaller numbers of deaths.
The researchers added, however, that treatment with aspirin during the trials lasted for only for between four and eight years on average, so the effects on risk of deaths due to cancer may underestimate possible results of longer-term treatment.
Peter Elwood, an expert on aspirin from Cardiff University's medical school who was not involved in this study, described aspirin as "a remarkable drug". "This risk of a bleed is so small compared to the benefits," he told reporters. "Yes, okay, it's a tragedy if a person is rushed into hospital and given a transfusion (because of a stomach bleed) but in relation to the things we are preventing, that is trivial."
Tuesday, December 7, 2010
Friday, December 3, 2010
Mercury poisoning makes male birds homosexual

01 December 2010 by Michael Marshall
Low levels of mercury in the diet of male white ibises cause the birds to mate with each other rather than with females. As a result many of the females can't breed, and fewer chicks are produced.
It's the first time a pollutant has been found to change an animal's sexual preference. Many chemicals can "feminise" males or reduce fertility, but males affected in these ways still prefer females.
Mercury is extremely toxic, particularly in the form of methylmercury, which reduces breeding in wild birds by disrupting their parenting behaviours. To find out if it also affected mating, Peter Frederick of the University of Florida in Gainesville and Nilmini Jayasena of the University of Peradeniya, Sri Lanka, captured 160 young white ibises from south Florida. They gave them food laced with methylmercury and monitored them closely.
The birds were split into four groups. One group ate food with 0.3 parts per million methylmercury, which most US states would regard as too high for human consumption. A second group got 0.1 ppm, and the third 0.05 ppm, a low dose that wild birds would be exposed to frequently. The fourth group received none.
Poisoned
All three dosed groups had significantly more homosexual males than the control group. Male-male pairs courted, built nests together and paired off for several weeks. Higher doses increased the effect, with 55 per cent of males in the 0.3 ppm group affected. Male-male matings were responsible for 81 per cent of unproductive nests in the dosed groups.
Meanwhile the heterosexual pairs courted less and were bad at parenting – patterns of behaviour that were both already known to be caused by methylmercury poisoning. The combined effects of male-male pairing and poor performance by male-female pairs could be severe. "In the worst-case scenario, the production of young would fall by 50 per cent," says Frederick.
Looking for effects on courtship and mating is novel, says Tony Scheuhammer of Environment Canada's National Wildlife Research Center in Ottawa, Ontario. "People normally study pairs that have already mated to see how good they are at parenting," he says.
Other birds would probably be similarly affected, though both Frederick and Scheuhammer say it's far from clear whether other animal groups would be. In particular, there's no evidence for increased homosexuality in humans resulting from mercury poisoning, despite several long-term studies. "If the effect was as strong in humans as in the ibises, they'd have found it," Frederick says.
Journal reference: Proceedings of the Royal Society B, DOI: 10.1098/rspb.2010.2189
Spray-On Stem Cells Speed Healing Process For Burn Victims
http://www.care2.com/causes/health-policy/blog/spray-on-stem-cells-accelerate-healing-for-burn-victims/

An experimental stem cell treatment is helping to speed up the healing process for burn victims, according to researchers at the University of Utah.
We've all heard of spray-on tans, and (ahem) clothing, but now the same principle of instant-application is being used to provide a speedy recovery process for those that are suffering from serious burns.
In clinical trials, surgeons Amit Patel and Amalia Cochran are testing "a concentrate of [the patient's own] platelets and progenitor cells with calcium and thrombin to create a Jello-like substance accelerates the healing process".
Popular Science reports that "in tests, the spray has proven effective in the treatment of small burns and seems to improve the likelihood that a skin graft will take, which could carry positive implications for the application of this technology to other types of transplants."
A similar treatment, called ReCell, is already being used in Australia, Europe and China and made headlines when it was used to treat of victims of a 2002 bombing in Bali.
So far, the spray-on treatment is only being used on patients with small burns, but the researchers hope that someday they maybe able to scale up the process to treat those who sustain burns on large areas of their body, like military personnel or people that have been caught in a house fire.

An experimental stem cell treatment is helping to speed up the healing process for burn victims, according to researchers at the University of Utah.
We've all heard of spray-on tans, and (ahem) clothing, but now the same principle of instant-application is being used to provide a speedy recovery process for those that are suffering from serious burns.
In clinical trials, surgeons Amit Patel and Amalia Cochran are testing "a concentrate of [the patient's own] platelets and progenitor cells with calcium and thrombin to create a Jello-like substance accelerates the healing process".
Popular Science reports that "in tests, the spray has proven effective in the treatment of small burns and seems to improve the likelihood that a skin graft will take, which could carry positive implications for the application of this technology to other types of transplants."
A similar treatment, called ReCell, is already being used in Australia, Europe and China and made headlines when it was used to treat of victims of a 2002 bombing in Bali.
So far, the spray-on treatment is only being used on patients with small burns, but the researchers hope that someday they maybe able to scale up the process to treat those who sustain burns on large areas of their body, like military personnel or people that have been caught in a house fire.
Monday, November 29, 2010
Harvard scientists reverse the aging process in mice – now for humans

http://www.guardian.co.uk/science/2010/nov/28/scientists-reverse-ageing-mice-humans
Harvard scientists reverse the ageing process in mice – now for humans
Harvard scientists were surprised that they saw a dramatic reversal, not just a slowing down, of the ageing in mice. Now they believe they might be able to regenerate human organs
Ian Sample, science correspondent
guardian.co.uk, Sunday 28 November 2010 18.01 GMT
In mice, reactivating the enzyme telomerase led to the repair of damaged tissues and reversed the signs of ageing. Photograph: Robert F. Bukaty/AP
Scientists claim to be a step closer to reversing the ageing process after rejuvenating worn out organs in elderly mice. The experimental treatment developed by researchers at Harvard Medical School turned weak and feeble old mice into healthy animals by regenerating their aged bodies.
The surprise recovery of the animals has raised hopes among scientists that it may be possible to achieve a similar feat in humans – or at least to slow down the ageing process.
An anti-ageing therapy could have a dramatic impact on public health by reducing the burden of age-related health problems, such as dementia, stroke and heart disease, and prolonging the quality of life for an increasingly aged population.
"What we saw in these animals was not a slowing down or stabilisation of the ageing process. We saw a dramatic reversal – and that was unexpected," said Ronald DePinho, who led the study, which was published in the journal Nature.
"This could lead to strategies that enhance the regenerative potential of organs as individuals age and so increase their quality of life. Whether it serves to increase longevity is a question we are not yet in a position to answer."
The ageing process is poorly understood, but scientists know it is caused by many factors. Highly reactive particles called free radicals are made naturally in the body and cause damage to cells, while smoking, ultraviolet light and other environmental factors contribute to ageing.
The Harvard group focused on a process called telomere shortening. Most cells in the body contain 23 pairs of chromosomes, which carry our DNA. At the ends of each chromosome is a protective cap called a telomere. Each time a cell divides, the telomeres are snipped shorter, until eventually they stop working and the cell dies or goes into a suspended state called "senescence". The process is behind much of the wear and tear associated with ageing.
At Harvard, they bred genetically manipulated mice that lacked an enzyme called telomerase that stops telomeres getting shorter. Without the enzyme, the mice aged prematurely and suffered ailments, including a poor sense of smell, smaller brain size, infertility and damaged intestines and spleens. But when DePinho gave the mice injections to reactivate the enzyme, it repaired the damaged tissues and reversed the signs of ageing.
"These were severely aged animals, but after a month of treatment they showed a substantial restoration, including the growth of new neurons in their brains," said DePinho.
Repeating the trick in humans will be more difficult. Mice make telomerase throughout their lives, but the enzyme is switched off in adult humans, an evolutionary compromise that stops cells growing out of control and turning into cancer. Raising levels of telomerase in people might slow the ageing process, but it makes the risk of cancer soar.
DePinho said the treatment might be safe in humans if it were given periodically and only to younger people who do not have tiny clumps of cancer cells already living, unnoticed, in their bodies.
David Kipling, who studies ageing at Cardiff University, said: "The goal for human tissue 'rejuvenation' would be to remove senescent cells, or else compensate for the deleterious effects they have on tissues and organs. Although this is a fascinating study, it must be remembered that mice are not little men, particularly with regard to their telomeres, and it remains unclear whether a similar telomerase reactivation in adult humans would lead to the removal of senescent cells."
Lynne Cox, a biochemist at Oxford University, said the study was "extremely important" and "provides proof of principle that short-term treatment to restore telomerase in adults already showing age-related tissue degeneration can rejuvenate aged tissues and restore physiological function."
DePinho said none of Harvard's mice developed cancer after the treatment. The team is now investigating whether it extends the lifespan of mice or enables them to live healthier lives into old age.
Tom Kirkwood, director of the Institute for Ageing and Health at Newcastle University, said: "The key question is what might this mean for human therapies against age-related diseases? While there is some evidence that telomere erosion contributes to age-associated human pathology, it is surely not the only, or even dominant, cause, as it appears to be in mice engineered to lack telomerase. Furthermore, there is the ever-present anxiety that telomerase reactivation is a hallmark of most human cancers."
Thursday, November 18, 2010
Merck cholesterol drug extremely effective in study
http://www.reuters.com/article/idUSN1719543320101117
Wed, Nov 17 2010
* Raises good HDL cholesterol 138 pct
* Cuts bad LDL cholesterol 40 pct in patients on statins
* No safety or torcetrapib-like problems observed
* 30,000-patient outcomes study to begin in 2011 Q2
By Bill Berkrot and Ransdell Pierson
NEW YORK/CHICAGO, Nov 17 (Reuters) - An experimental Merck & Co (MRK.N: Quote, Profile, Research, Stock Buzz) heart drug, from a class of medicine with a troubled past, appeared to be safe and had a "jaw dropping" effect on both good and bad cholesterol levels, according to data from a clinical trial.
Merck's anacetrapib increased good HDL levels by a stunning 138 percent after 24 weeks of treatment, and lowered levels of bad LDL cholesterol by 40 percent in patients already taking LDL-lowering statins, researchers said.
"The lipid effects are jaw dropping in both directions," said Dr. Christopher Cannon, the study's lead investigator from Brigham and Women's Hospital in Boston. He presented the data at the American Heart Association scientific meeting in Chicago on Wednesday.
Researchers found no anacetrapib safety issues during the 18-month study, and patients receiving the drug had fewer serious heart problems than those given a placebo.
Even if development of the medicine continues without a hitch, it will likely be at least five years before Merck can begin selling the drug.
Anacetrapib belongs to a class of drugs called CETP inhibitors that produced one of the most spectacular clinical failures in pharmaceutical history. A pivotal study of Pfizer Inc's (PFE.N: Quote, Profile, Research, Stock Buzz) highly touted torcetrapib was stopped in late 2006 after higher death rates were found among those taking the drug, pulling the plug on an $800 million Phase III program.
Based on the data from the anacetrapib trial, called Define, "we are 94 percent confident that anacetrapib doesn't have the clinical (side) effects of torcetrapib," Cannon said.
The HDL increase seen with anacetrapib "is double what torcetrapib does; it's four times what niacin can do if you can push niacin to its full 2 gram dose; and 10 times the effect seen with statins," Cannon said, comparing anacetrapib with other therapies.
It is believed that HDL has a heart protective effect, possibly by carrying LDL away from the arteries.
Anacetrapib also cut by 36 percent levels of LP(a), which is believed to be an independent cardiovascular risk factor.
The 1,623-patient, 18-month Define trial was designed to show anacetrapib does not have the unintended effects on blood chemistry and blood pressure found in detailed analyses of what went wrong with the Pfizer drug.
"It's been found that torcetrapib unfortunately as a molecule somehow lands itself in the adrenal gland and then pumps out aldosterone, other hormones, and has all these effects," Cannon explained.
Compared with the placebo group, patients receiving anacetrapib in the study showed no difference in electrolytes, aldosterone or blood pressure, and no other safety concerns were seen with the drug, he said.
"This trial was set up so that we would have some more reassurance that the drug was safe before doing a gigantic trial. And that's what we found, that it looks safe so far," Cannon said.
In the wake of torcetrapib, Merck has long known that to gain approval for anacetrapib, it will have to conduct a large so-called outcomes trial to prove its drug cuts heart attacks and death rather than just impacts cholesterol levels.
Plans for such a study were announced on Wednesday. It will include some 30,000 patients at high risk of heart attack or other serious heart problems, and take about four years to complete. Enrollment is expected to begin in the second quarter of 2011, researchers said.
Patients in the 18-month Define study all had coronary disease or were at high risk for heart disease, and were already taking a statin, such as Lipitor, to lower their LDL levels. They received either 100 milligrams of anacetrapib or a placebo once a day on top of their statin.
At the start of the study, patients on average had a baseline HDL of 40 and LDL of 81. Those on anacetrapib on average saw HDL leap to 101 and LDL drop to 45. HDL levels of placebo patients rose only to 46, while LDL fell to 77.
Patients whose LDL dropped below 25 were taken off the drug as a precaution, which was part of the study's design. "We didn't see any problems, but this gets the LDL down as low as its ever been in any study," Cannon said.
Researchers observed a trend toward lower rates of cardiovascular death, heart attack, stroke and hospitalization for unstable angina. The need for angioplasty or bypass surgery over 18 months was significantly lower on anacetrapib -- eight patients versus 28 on placebo.
While the dramatic impact on HDL is clear, it remains to be determined if raising it through the CETP inhibitor mechanism can save lives and hospitalizations.
Roche (ROG.VX: Quote, Profile, Research, Stock Buzz) and Japan Tobacco (2914.T: Quote, Profile, Research, Stock Buzz) are also forging ahead with development of a CETP inhibitor, called dalcetrapib.
"There is very real uncertainty as to what anacetrapib will do on clinical outcomes," said Rory Collins, co-director of the clinical trial service unit at the University of Oxford, who will lead the outcomes study program.
"It is incredibly exciting. It could be really the next big thing in cardiovascular disease," Collins said. (Reporting by Bill Berkrot and Randell Pierson; editing by John Wallace)
Wed, Nov 17 2010
* Raises good HDL cholesterol 138 pct
* Cuts bad LDL cholesterol 40 pct in patients on statins
* No safety or torcetrapib-like problems observed
* 30,000-patient outcomes study to begin in 2011 Q2
By Bill Berkrot and Ransdell Pierson
NEW YORK/CHICAGO, Nov 17 (Reuters) - An experimental Merck & Co (MRK.N: Quote, Profile, Research, Stock Buzz) heart drug, from a class of medicine with a troubled past, appeared to be safe and had a "jaw dropping" effect on both good and bad cholesterol levels, according to data from a clinical trial.
Merck's anacetrapib increased good HDL levels by a stunning 138 percent after 24 weeks of treatment, and lowered levels of bad LDL cholesterol by 40 percent in patients already taking LDL-lowering statins, researchers said.
"The lipid effects are jaw dropping in both directions," said Dr. Christopher Cannon, the study's lead investigator from Brigham and Women's Hospital in Boston. He presented the data at the American Heart Association scientific meeting in Chicago on Wednesday.
Researchers found no anacetrapib safety issues during the 18-month study, and patients receiving the drug had fewer serious heart problems than those given a placebo.
Even if development of the medicine continues without a hitch, it will likely be at least five years before Merck can begin selling the drug.
Anacetrapib belongs to a class of drugs called CETP inhibitors that produced one of the most spectacular clinical failures in pharmaceutical history. A pivotal study of Pfizer Inc's (PFE.N: Quote, Profile, Research, Stock Buzz) highly touted torcetrapib was stopped in late 2006 after higher death rates were found among those taking the drug, pulling the plug on an $800 million Phase III program.
Based on the data from the anacetrapib trial, called Define, "we are 94 percent confident that anacetrapib doesn't have the clinical (side) effects of torcetrapib," Cannon said.
The HDL increase seen with anacetrapib "is double what torcetrapib does; it's four times what niacin can do if you can push niacin to its full 2 gram dose; and 10 times the effect seen with statins," Cannon said, comparing anacetrapib with other therapies.
It is believed that HDL has a heart protective effect, possibly by carrying LDL away from the arteries.
Anacetrapib also cut by 36 percent levels of LP(a), which is believed to be an independent cardiovascular risk factor.
The 1,623-patient, 18-month Define trial was designed to show anacetrapib does not have the unintended effects on blood chemistry and blood pressure found in detailed analyses of what went wrong with the Pfizer drug.
"It's been found that torcetrapib unfortunately as a molecule somehow lands itself in the adrenal gland and then pumps out aldosterone, other hormones, and has all these effects," Cannon explained.
Compared with the placebo group, patients receiving anacetrapib in the study showed no difference in electrolytes, aldosterone or blood pressure, and no other safety concerns were seen with the drug, he said.
"This trial was set up so that we would have some more reassurance that the drug was safe before doing a gigantic trial. And that's what we found, that it looks safe so far," Cannon said.
In the wake of torcetrapib, Merck has long known that to gain approval for anacetrapib, it will have to conduct a large so-called outcomes trial to prove its drug cuts heart attacks and death rather than just impacts cholesterol levels.
Plans for such a study were announced on Wednesday. It will include some 30,000 patients at high risk of heart attack or other serious heart problems, and take about four years to complete. Enrollment is expected to begin in the second quarter of 2011, researchers said.
Patients in the 18-month Define study all had coronary disease or were at high risk for heart disease, and were already taking a statin, such as Lipitor, to lower their LDL levels. They received either 100 milligrams of anacetrapib or a placebo once a day on top of their statin.
At the start of the study, patients on average had a baseline HDL of 40 and LDL of 81. Those on anacetrapib on average saw HDL leap to 101 and LDL drop to 45. HDL levels of placebo patients rose only to 46, while LDL fell to 77.
Patients whose LDL dropped below 25 were taken off the drug as a precaution, which was part of the study's design. "We didn't see any problems, but this gets the LDL down as low as its ever been in any study," Cannon said.
Researchers observed a trend toward lower rates of cardiovascular death, heart attack, stroke and hospitalization for unstable angina. The need for angioplasty or bypass surgery over 18 months was significantly lower on anacetrapib -- eight patients versus 28 on placebo.
While the dramatic impact on HDL is clear, it remains to be determined if raising it through the CETP inhibitor mechanism can save lives and hospitalizations.
Roche (ROG.VX: Quote, Profile, Research, Stock Buzz) and Japan Tobacco (2914.T: Quote, Profile, Research, Stock Buzz) are also forging ahead with development of a CETP inhibitor, called dalcetrapib.
"There is very real uncertainty as to what anacetrapib will do on clinical outcomes," said Rory Collins, co-director of the clinical trial service unit at the University of Oxford, who will lead the outcomes study program.
"It is incredibly exciting. It could be really the next big thing in cardiovascular disease," Collins said. (Reporting by Bill Berkrot and Randell Pierson; editing by John Wallace)
Monday, November 1, 2010
Researchers Grow a Liver in a Lab Setting

Researchers have created a buzz in the organ transplant world by growing a liver in a lab setting. However, this liver may function just like any other liver but it is miniature, a test to see if the technology was possible. The group used stem cells to create the liver which is said to be genetically identical to that of a human liver.
The idea that human organs can be grown in labs has been the stuff of science fiction novels for years. However, it has become a reality these days. Still, the researchers have said that it will be years before the technology and science are advanced far enough to create full size organs.
When the advancements are complete it will revolutionize the transplant world. Patients will no longer have to wait years for a new organ when one can be specifically grown for them in a lab setting.
One issue is the fact that these organs are designed by using stem cell research. This gives them a specific DNA structure that must be unique to the patient. Stem cell research has only recently restarted in the US after President Obama lifted a ban imposed by former President Bush.
Organ transplants are a hot commodity in this world today. Black markets buy and sell organs through underground medical facilities, often causing fatalities when the patients develop infections from unsterile conditions.
With the advancement of lab grown organs research may be able to save the lives of millions every year.
Short URL: http://thenewsportalonline.com/?p=3946
Thursday, August 26, 2010
Brain Connections Break Down as We Age, Study Suggests

http://www.sciencedaily.com/releases/2010/08/100818151822.htm
The circled portion of the older adult' brain on the left indicates the cross-talk between the two hemispheres that is not apparent in the younger brain on the right. Click above image for higher resolution. (Credit: Rachael Seidler)
ScienceDaily (Aug. 19, 2010) — It's unavoidable: breakdowns in brain connections slow down our physical response times as we age, a new study suggests.
This slower reactivity is associated with an age-related breakdown in the corpus callosum, a part of the brain that acts as a dam during one-sided motor activities to prevent unwanted connectivity, or cross-talk, between the two halves of the brain, said Rachael Seidler, associate professor in the University of Michigan School of Kinesiology and Department of Psychology, and lead study author.
At other times the corpus callosum acts at a bridge and cross-talk is helpful, such as in certain cognitive functions or two-sided motor skills.
The U-M study is the first known to show that this cross-talk happens even while older adults are at rest, said Seidler, who also has appointments in the Institute of Gerontology and the Neuroscience Graduate Program. This resting cross-talk suggests that it is not helpful or compensatory for the two halves of the brain to communicate during one-sided motor movements because the opposite side of the brain controls the part of the body that is moving. So, when both sides of the brain talk simultaneously while one side of the body tries to move, confusion and slower responses result, Seidler said.
Previous studies have shown that cross-talk in the brain during certain motor tasks increases with age but it wasn't clear if that cross-talk helped or hindered brain function, said Seidler.
"Cross-talk is not a function of task difficulty, because we see these changes in the brain when people are not moving," Seidler said.
In some diseases where the corpus callosum is very deteriorated, such as in people with multiple sclerosis, you can see "mirror movements" during one sided-motor tasks, where both sides move in concert because there is so much communication between the two hemispheres of the brain, Seidler said. These mirror movements also happen normally in very young children before the corpus callosum is fully developed.
In the study, researchers gave joysticks to adults between the ages of 65 and 75 and measured and compared their response times against a group approximately 20-25 years old.
Researchers then used a functional MRI to image the blood-oxygen levels in different parts of the brain, a measurement of brain activity.
"The more they recruited the other side of the brain, the slower they responded," Seidler said.
However there is hope, and just because we inevitably age doesn't mean it's our fate to react more slowly. Seidler's group is working on developing and piloting motor training studies that might rebuild or maintain the corpus callosum to limit overflow between hemispheres, she said.
A previous study done by another group showed that doing aerobic training for three months helped to rebuild the corpus callosum, she said, which suggests that physical activity can help to counteract the effects of the age-related degeneration.
Seidler's group also has a study in review that uses the same brain imaging techniques to examine disease related brain changes in Parkinson's patients.
The study appeared in the journal Frontiers in Systems Neuroscience.
Subscribe to:
Posts (Atom)